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ERAs are only 
conducted on 
pharmaceuticals 
licenced after 
2006.6
At each stage of a pharmaceutical lifecycle, there is a significant risk of environmental exposure. For this reason, it is imperative to
implement both source directed and end of pipe control measures. This will mitigate any potential hazards to the environment or to
humans. The ever-increasing use and availability of pharmaceuticals in the last decade have led to the contamination of surface
water ecosystems with ng/L to µg/L concentrations. The environmental fate and toxicological implications of many pharmaceuticals
and their residues are not fully understood. Additionally, the stability and biological activity of these “micro-pollutants” can lead to
chronic environmental exposure causing behavioural and health-related effects. This research investigates pharmaceuticals chosen
from the updated surface water “Watch List” (Decision (EU) 2018/840), followed by pharmaceuticals which are commonly found in
European surface water and pharmaceuticals which have a low removal efficiency in wastewater treatment plants.1 This project
aims to create a comprehensive prioritisation framework and a risk-based assessment by calculating their risk quotient for each of
the chosen pharmaceuticals.
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Lifecycle Assessment of Pharmaceuticals in Irish Surface Waters
Each of these chosen pharmaceuticals have been identified as Contaminants of Emerging Concern (CECs).2 However, it is not just a
single pharmaceutical in the environment, it is a chemical cocktail of many different types and their associated metabolites. This
cocktail can lead to an unknown toxicity within the environment and to humans.
Introduction:
Life cycle of pharmaceuticals 
Pharmaceuticals commonly found in surface water
Climate change!
Droughts and floods can drastically
alter the dilution of pharmaceuticals in
surface water. This can lead to
pollution events where the toxic effects
of pharmaceuticals are heightened.5
of 398 people questioned in Cork 
and Galway had said they have 
improperly disposed of medicine in 
the past.4
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Factors influencing environmental concentrations and risk assessment
Water Framework Directive priority chemical
Water Framework Directive watch list chemicals
CECs with low removal efficiency 
Erythromycin
0.8-174.73 ng/L
Clarithromycin
1.26-141 ng/L
Azithromycin
1-71.67 ng/LTrimethoprim
0.1-317.2 ng/L
Sulfamethoxazole
1.5-330 ng/L
Amoxicillin
1.16 ng/L
17 α-ethinylestradiol
1.16-117 ng/L
17 β-estradiol
0.449-14.1 ng/L
Estrone
0.05-29.2 ng/L
Gemfibrozil
0.91-326 ng/L
Carbamazepine
0.2-1705 ng/L
Ciprofloxacin
1-93.3 ng/L
Diclofenac
0.5-2550 ng/L
Phase 1
Phase II A
Phase II B
• Screening pharmaceuticals for their 
physiochemical properties and their 
predicted environmental concentration.
• Examining  the fate and 
effect of pharmaceuticals  
in the environment 
• Refining risk assessment 
and further testing 
Environmental Risk assessment (ERA) for human medicine
If risks 
are found
If risks 
are found
